Country websites

We continue to shape the future of the dialysis industry.

Outlook 2026

Outlook 2026 as updated on November 3, 2026

 FY 2025Outlook 2026
(at constant currencies)
Revenue growthEUR 19,628 millionBroadly flat
Operating Income growthEUR 2,212 millionFlat to negative
mid-single digit percent

 

Outlook 2026 is based on current assumptions and excludes special items. Special items include the costs related to the FME25+ Program, the impacts from Legacy Portfolio Optimization, the Humacyte Remeasurements and the Tavneos Impacts as well as other effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. The outlook assumes current laws, policies, regulations, and tariffs. The growth rates are based on the results 2025 excluding the costs related to the FME25+ Program (€194 M for operating income), the impacts from Legacy Portfolio Optimization (€97 M for operating income), the Legal Form Conversion Costs (€4 M for operating income) and the Humacyte Remeasurements (€90 M for operating income).

2028 and 2030 Aspirations  

Fresenius Medical Care aspires operating income growth (CAGR) of between 3 and 7 percent between 2025 and 2028.

Revenue growth (CAGR) between 2025 and 2030

 FY 2025Aspirations 2030
(at constant currencies)

Care Delivery

EUR 13,736 million

Low- to mid-single digit percent

Care Enablement

EUR 5,476 million

Mid-single digit percent

 

Value-Based Care is excluded 

Operating income margin aspirations by 2030

 FY 2025Aspirations 2030

Fresenius Medical Care Group

11.3%

Mid-teens

Care Delivery

13.1%

Mid-teens

Care Enablement

8.1%

Mid-teens

Value-Based Care

0.1%

Low-single digit

 

The assumed growth rates are at constant currency and exclude special items. The assumed margins exclude special items in operating income. Margin in percent of revenue.

Contact us for further information

+49 6172 609 2525

Related Content